All In Biotech

Drug Trial Radar · NCT03770000

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor Given in Combination With a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients With Relapsed/Refractory T-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Oct 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

33

Actual

Start

Mar 12, 2019

Primary completion

May 14, 2021

Study completion May 14, 2021

Sponsor

Lead sponsor
Rhizen Pharmaceuticals SAIndustry
Sponsor type
Industry
First posted
Dec 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.

Conditions

  • T Cell Lymphoma

Interventions

  • TenalisibDrug

    Tenalisib, BID orally daily

  • RomidepsinDrug

    Romidepsin IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With and Without Dose Limiting Toxicities (DLTs)Time frame: 28 days

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • University of California, Hellen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • University of Miami-Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Rush University Cancer Center

    Chicago, Illinois

  • The University of Kansas Cancer Center

    Fairway, Kansas

  • Norton Cancer Institute, St Matthews Campus

    Louisville, Kentucky

  • University of Michigan

    Ann Arbor, Michigan

  • John Theurer Cancer Center, Hackensack University Medical Center

    Hackensack, New Jersey

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Cleveland Clinic Taussig Cancer Institute

    Cleveland, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center,

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.